替诺福韦节约方案时代:HIV治疗与预防中HBV感染及再激活风险
替诺福韦节约型抗逆转录病毒治疗(ART)和暴露前预防(PrEP)日益增多,但因对HBV无完全活性,可能增加新发HBV感染或再激活风险。风险大小与机制因基线HBV血清学状态而异,换药前需与患者讨论。通过HBV筛查、疫苗接种和换药后监测可降低风险。本文综合不同临床场景证据,提出实用工作流程,并指出知识空白与未来研究方向。
要点
- 替诺福韦节约方案对HBV无完全活性,可致新发感染或再激活。
- 换药前应评估基线HBV血清学状态并讨论风险。
- HBV筛查、疫苗接种和换药后监测可降低风险。
核心结论
- 切换至替诺福韦节约型ART或PrEP的决定不应仅基于HIV疗效和便利性,必须纳入HBV预防和再激活风险。
研究设计与样本
- 本文为综述,综合不同临床场景的证据并提出实用工作流程。
主要发现
- 替诺福韦节约型ART和PrEP因缺乏对HBV的完全活性,可能增加新发HBV感染或再激活风险。
- 风险的大小和机制因基线HBV血清学特征而异。
- 通过HBV筛查、疫苗接种和换药后监测可降低这些风险。
临床怎么用
- 换药前应评估基线HBV血清学状态并与患者讨论风险。
- 实施HBV筛查、疫苗接种和换药后监测以降低风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tenofovir-sparing antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) are increasingly used. However, these regimens may increase the risk of new hepatitis B virus (HBV) infection or reactivation due to lack of full activity against HBV. The magnitude and mechanism of risk can vary by baseline HBV serologic profile and need to be discussed with the patient before switching regimens. Importantly, these risks can be mitigated through HBV screening, vaccination, and post-switch monitoring. Here, we synthesize the evidence across different clinical scenarios and propose a practical workflow to reduce the potential but preventable risk during transitions to tenofovir-sparing regimens. Finally, we highlight knowledge gaps and outline future research priorities. The decision to switch to tenofovir-sparing ART or PrEP should not be made solely through the lens of HIV efficacy and convenience and must incorporate HBV prevention and reactivation risk.
引用
- Lee TH, Bhattacharya D, Kim HN, et al. Don't Drop the B: Risk of Hepatitis B Virus Infection and Reactivation in the Era of Tenofovir-Sparing Regimens for Treatment and Prevention of HIV. Clin Infect Dis. 2026. PMID: 42200461. doi:10.1093/cid/ciag322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。